tbuckley/cabot-search huggingface dataset:
Abstract MP265: The Role Of Phosphodiesterase 10a In Tumor Growth And Doxorubicin-induced Cardiotoxicity
Authors: Si Chen, Jiawei Chen, Hangchuan Shi, Deanne Mickelsen, Chen Yan
Journal: Circulation Research (2021)

Cyclic nucleotide phosphodiesterases (PDEs), through the degradation of cyclic nucleotides, play critical roles in cardiovascular biology and disease. PDE10A is able to hydrolyze both cAMP and cGMP. Its high expression in medium spiny neurons of the human striatum has led to the development of several PDE10A inhibitors with the intent to treat various psychiatric/neurodegenerative disorders, such as schizophrenia and Huntington's disease. Our previous study has reported the upregulation of PDE10A expression in failing hearts and demonstrated the protective effects of PDE10A deficiency/inhibition against cardiac hypertrophy, fibrosis, and dysfunction in mouse models of heart failure. Doxorubicin (DOX) is an effective chemotherapeutic agent against a variety of cancers. While its therapeutic utility is limited by the development of dose-dependent cardiotoxicity. In the current study, we aim to determine the role of PDE10A in cancer and cardiotoxicity induced by DOX. We found that PDE10A inhibition or deficiency alleviated DOX-induced cardiotoxicity in vivo, as well as cardiac myocyte (CM) death and atrophy in vitro. In ovarian cancer cells, PDE10A inhibition induced cell death and reduced cell proliferation; as well as potentiated the effect of DOX on antagonizing cancer cells. Interestingly, in nude mice with ovarian cancer xenografts, PDE10A inhibition attenuated ovarian tumor growth while protected DOX-induced cardiotoxicity. RNAseq and bioinformatics analysis uncovered a number of PDE10A-regulated signaling pathways and cellular processes involved in DOX-induced cardiotoxicity. Mechanistic studies further revealed that PDE10A regulates CM death and atrophy via different mechanistic actions: regulating CM death via a cGMP-dependent while cAMP-independent mechanism; and regulating CM atrophy via a mechanism dependent on both cGMP and cAMP. Several PDE10A inhibitors have been tested in humans and successfully passed phase I clinical trials for safety. Thus, our findings suggest that PDE10A may be a safe "druggable" target for cancer therapy by simultaneously preventing DOX-induced cardiotoxicity and antagonizing tumor growth.
Diabetic Peripheral Neuropathy and Urological Complications in Type 1 Diabetes: Findings From the Epidemiology of Diabetes Interventions and Complications Study
Authors: Rodica Pop-Busui, Barbara H. Braffett, Hunter Wessells, William H. Herman, Catherine L. Martin, Alan M. Jacobson, Aruna V. Sarma
Journal: Diabetes Care (2021)

OBJECTIVE To evaluate associations between diabetic peripheral neuropathy (DPN) and urological complications in men and women with type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS Measurements of DPN at Epidemiology of Diabetes Intervention and Complications (EDIC) years 1, 14, and 17 and urological complications at EDIC year 17 were examined in 635 men (mean age 51.6 years, diabetes duration 29.5 years) and 371 women (mean age 50.6 years, diabetes duration 29.8 years) enrolled in the Diabetes Control and Complications Trial (DCCT)/EDIC study. DPN was defined by symptoms, signs, and abnormal electrophysiology or by abnormal Michigan Neuropathy Screening Instrument (MNSI) examination or questionnaire scores. RESULTS Erectile dysfunction (ED) in combination with lower urinary tract symptoms (LUTS) was reported in 15% of men and female sexual dysfunction (FSD), LUTS, and urinary incontinence (UI) in 16% of women. Adjusted for age, drinking status, BMI, depression, DCCT/EDIC time-weighted mean HbA1c, microalbuminuria, hypertension, triglycerides, and statin medication use, the odds of reporting ED and LUTS versus no ED or LUTS at EDIC year 17 were 3.52 (95% CI 1.69, 7.31) times greater in men with confirmed DPN at EDIC year 13/14 compared to men without confirmed DPN. Compared to men without DPN, men with DPN based on abnormal MNSI examination or questionnaire scores had significantly higher odds of reporting ED and LUTS versus no ED or LUTS at EDIC year 17. There were no significant differences in DPN between women reporting both FSD and LUTS/UI compared with those without FSD or LUTS/UI at EDIC year 17. CONCLUSIONS In long-standing T1D, DPN is associated with the later development of urological complications in men.
HPV vaccine cut cervical cancer rates in England by 87%
Authors: Ingrid Torjesen
Journal: BMJ (2021)

The human papillomavirus vaccine has reduced the incidence of cervical cancer by 87% in women in their 20s in England who were offered the vaccine when they were aged 12-13 years as part of the UK HPV vaccination programme, a study published in the Lancet shows.1

Michelle Mitchell, chief executive of the charity Cancer Research UK, hailed the results as a “historic moment” that demonstrated the power of science.

The UK HPV vaccination programme was introduced in 2008, offering vaccines to girls aged 12-13, with a “catch-up” programme of vaccinations offered up to the age of 18.

The Lancet ’s population based study used cancer registry data to compare the incidence of cervical cancer and non-invasive cervical carcinoma (CIN3) in seven cohorts of …
The failure of provision for neurodiverse children during the covid-19 pandemic
Authors: Rakhee Shah, Michael Absoud
Journal: BMJ (2021)

<h3>Abstract</h3> <i>Nippostrongylus brasiliensis</i> is a well-defined model of type 2 immunity but the early lung-migrating phase is dominated by innate IL-17A production and neutrophilia. While the importance of IL-17A is well established during microbial infections, its contribution to type 2 immunity is poorly understood. Using <i>N. brasiliensis</i> infection we show that <i>Il17a</i>-KO mice exhibited an impaired type 2 immune response correlating with increased worm burden. Neutrophil depletion and reconstitution studies demonstrated that neutrophils contributed to the subsequent eosinophilia but were not responsible for the ability of IL-17A to promote type 2 cytokine responses. Transcriptional profiling of the lung on day 2 of <i>N. brasiliensis</i> infection revealed an increased IFNγ signature in the <i>Il17a</i>-KO mice confirmed by enhanced IFNγ protein production. Depletion of early IFNγ restored type 2 immune responses in the <i>Il17a</i>-KO mice supporting the hypothesis that the suppression of IFNγ by innate IL-17A sources promotes the protective type 2 immune response. Notably, when IL-17A was blocked later in infection, there was an increased type 2 response. Combined data from both <i>N. brasiliensis</i> and <i>Trichuris muris</i>, a gut-specific pathogen, demonstrated that IL-17A regulation of type 2 immunity was lung-specific. Together our data suggest that IL-17A is a major regulator of type 2 immunity in the lung which supports the development of a protective type 2 immune response but subsequently limits the magnitude of that response.
Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study
Authors: Antonio Tursi, Giovanni Brandimarte, Francesco Di Mario, Walter Elisei, Marcello Picchio, Leonardo Allegretta, Maria Laura Annunziata, Mauro Bafutto, Gabrio Bassotti, Maria Antonietta Bianco, Raffaele Colucci, Rita Conigliaro, Dan Dumitrascu, Ricardo Escalante, Luciano Ferrini, Giacomo Forti, Marilisa Franceschi, Maria Giovanna Graziani, Frank Lammert, Giovanni Latella, Giovanni Maconi, Gerardo Nardone, Lucia Camara de Castro Oliveira, Enio Chaves Oliveira, Alfredo Papa, Savvas Papagrigoriadis, Anna Pietrzak, Stefano Pontone, Tomas Poskus, Giuseppe Pranzo, Matthias Christian Reichert, Stefano Rodinò, Jaroslaw Regula, Giuseppe Scaccianoce, Franco Scaldaferri, Roberto Vassallo, Costantino Zampaletta, Angelo Zullo, Daniele Piovani, Stefanos Bonovas, Silvio Danese
Journal: Gut (2021)

Objective To investigate the predictive value of the Diverticular Inflammation and Complication Assessment (DICA) classification and to develop and validate a combined endoscopic-clinical score predicting clinical outcomes of diverticulosis, named Combined Overview on Diverticular Assessment (CODA). Design A multicentre, prospective, international cohort study. Setting 43 gastroenterology and endoscopy centres located in Europe and South America. Participants 2215 patients (2198 completing the study) at the first diagnosis of diverticulosis/diverticular disease were enrolled. Patients were scored according to DICA classifications. Interventions A 3-year follow-up was performed. Main outcome measures To predict the acute diverticulitis and the surgery according to DICA classification. Survival methods for censored observation were used to develop and validate a novel combined endoscopic-clinical score for predicting diverticulitis and surgery (CODA score). Results The 3-year cumulative probability of diverticulitis and surgery was of 3.3% (95% CI 2.5% to 4.5%) in DICA 1, 11.6% (95% CI 9.2% to 14.5%) in DICA 2 and 22.0% (95% CI 17.2% to 28.0%) in DICA 3 (p&lt;0.001), and 0.15% (95% CI 0.04% to 0.59%) in DICA 1, 3.0% (95% CI 1.9% to 4.7%) in DICA 2 and 11.0% (95% CI 7.5% to 16.0%) in DICA 3 (p&lt;0.001), respectively. The 3-year cumulative probability of diverticulitis and surgery was ≤4%, and ≤0.7% in CODA A; &lt;10% and &lt;2.5% in CODA B; &gt;10% and &gt;2.5% in CODA C, respectively. The CODA score showed optimal discrimination capacity in predicting the risk of surgery in the development (c-statistic: 0.829; 95% CI 0.811 to 0.846) and validation cohort (c-statistic: 0.943; 95% CI 0.905 to 0.981). Conclusions DICA classification has a significant role in predicting the risk of diverticulitis and surgery in patients with diverticulosis, which is significantly enhanced by the CODA score. Trial registration number NCT02758860 .
A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant
Authors: Irene Rossi, Gloria Spagnoli, Francesca Buttini, Fabio Sonvico, Fabio Stellari, Davide Cavazzini, Quigxin Chen, Martin Müller, Angelo Bolchi, Simone Ottonello, Ruggero Bettini
Journal: Journal of Controlled Release (2021)
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean
Authors: Gustavo Werutsky, Carlos H Barrios, Andres F Cardona, André Albergaria, Alfonso Valencia, Carlos G Ferreira, Christian Rolfo, Evandro de Azambuja, Gabriel A Rabinovich, Georgina Sposetti, Oscar Arrieta, Rodrigo Dienstmann, Taiane F Rebelatto, Valeria Denninghoff, Veronica Aran, Eduardo Cazap
Journal: The Lancet Oncology (2021)
First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios
Authors: Rafael Fonseca, Thierry Facon, Mahmoud Hashim, Sandhya Nair, Jianming He, Eric M. Ammann, Annette Lam, Mark Wildgust, Shaji Kumar
Journal: Blood (2021)
Both‐In‐One Hybrid Bacteria Suppress the Tumor Metastasis and Relapse via Tandem‐Amplifying Reactive Oxygen Species‐Immunity Responses (Adv. Healthcare Mater. 21/2021)
Authors: Mengchi Sun, Hao Ye, Qinghua Shi, Jun Xie, Xiang Yu, Hao Ling, Song You, Zhonggui He, Bin Qin, Jin Sun
Journal: Advanced Healthcare Materials (2021)

Synergistic Cancer Therapy In article number 2100950 by Bin Qin, Jin Sun, and co-workers, a both-in-one hybrid bacteria, wherein the chemotherapeutic drug doxorubicin is integrated onto the surface of glucose dehydrogenase-overexpressed non-pathogenic Escherichia coli strain, potentiates stimulated systemic antitumor immune responses, thereby significantly inhibiting tumor metastasis, postsurgical regrowth, and primary/distal tumor relapse in four different tumor models.
RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity
Authors: Zhuo Zhang, Lin Luo, Chuan Xing, Yu Chen, Peng Xu, Mao Li, Ling Zeng, Chao Li, Sadashib Ghosh, Deborah Della Manna, Tim Townes, William J. Britt, Narendra Wajapeyee, Barry P. Sleckman, Zechen Chong, Jianmei Wu Leavenworth, Eddy S. Yang
Journal: Nature Cancer (2021)
Chromatin Remodelers Interact with Eya1 and Six2 to Target Enhancers to Control Nephron Progenitor Cell Maintenance
Authors: Jun Li, Jinshu Xu, Huihui Jiang, Ting Zhang, Aarthi Ramakrishnan, Li Shen, Pin-Xian Xu
Journal: Journal of the American Society of Nephrology (2021)

Significance Statement Understanding how the precise gene expression states that define nephron progenitor cell identity are established and maintained is crucial for developing approaches to repair or regenerate the damaged nephron. Combination of Eya1-Six1/2 has been explored in inducing nephron progenitor–like cell reprogramming. This study uncovers a critical role for chromatin-remodeling SWI/SNF complex through interactions with Eya1-Six2 in nephron fate induction and maintenance and identifies critical factors, including Pbx1, as direct targets of SWI/SNF and Eya1-Six2. The properties of chromatin remodelers as transcriptional coregulators and Pbx1 in hematopoietic stem cell self-renewal suggest that they may be combined with Eya1-Six1/2 in reprogramming nephrons. Background Eya1 is a critical regulator of nephron progenitor cell specification and interacts with Six2 to promote NPC self-renewal. Haploinsufficiency of these genes causes kidney hypoplasia. However, how the Eya1-centered network operates remains unknown. Methods We engineered a 2×HA-3×Flag-Eya1 knock-in mouse line and performed coimmunoprecipitation with anti-HA or -Flag to precipitate the multitagged-Eya1 and its associated proteins. Loss-of-function, transcriptome profiling, and genome-wide binding analyses for Eya1's interacting chromatin-remodeling ATPase Brg1 were carried out. We assayed the activity of the cis -regulatory elements co-occupied by Brg1/Six2 in vivo . Results Eya1 and Six2 interact with the Brg1-based SWI/SNF complex during kidney development. Knockout of Brg1 results in failure of metanephric mesenchyme formation and depletion of nephron progenitors, which has been linked to loss of Eya1 expression. Transcriptional profiling shows conspicuous downregulation of important regulators for nephrogenesis in Brg1-deficient cells, including Lin28, Pbx1, and Dchs1-Fat4 signaling, but upregulation of podocyte lineage, oncogenic, and cell death–inducing genes, many of which Brg1 targets. Genome-wide binding analysis identifies Brg1 occupancy to a distal enhancer of Eya1 that drives nephron progenitor–specific expression. We demonstrate that Brg1 enrichment to two distal intronic enhancers of Pbx1 and a proximal promoter region of Mycn requires Six2 activity and that these Brg1/Six2-bound enhancers govern nephron progenitor–specific expression in response to Six2 activity. Conclusions Our results reveal an essential role for Brg1, its downstream pathways, and its interaction with Eya1-Six2 in mediating the fine balance among the self-renewal, differentiation, and survival of nephron progenitors.
TCT-294 A Novel Risk Score to Identify AF Patients Undergoing PCI at High Thrombotic Risk a RE-DUAL PCI Secondary Analysis
Authors: Bastiaan Zwart, Wilbert Bor, Anne de Veer, Bakhtawar Mahmoodi, Johannes Kelder, Gregory Lip, Deepak Bhatt, Christopher Cannon, Jurrien Ten Berg
Journal: Journal of the American College of Cardiology (2021)
Lack of CD8 <sup>+</sup> T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer
Authors: Brendan L. Horton, Duncan M. Morgan, Noor Momin, Maria Zagorulya, Elen Torres-Mejia, Vidit Bhandarkar, K. Dane Wittrup, J. Christopher Love, Stefani Spranger
Journal: Science Immunology (2021)

A lung cancer–specific form of CD8 + T cell dysfunction is established during T cell priming and contributes to ICB resistance.
Abstract 15295: Cardiac Sympathetic Afferent Stimulation Increases Brain ENaCs, thereby Concomitant Salt Loading Leads to Sympathoexcitation
Authors: Koji Ito, Yoshitaka Hirooka, Kenji Sunagawa
Journal: Circulation (2012)

Background: Recently, we demonstrated in mice with pressure overload, brain epithelial Na channels (ENaCs) increased and concomitant salt loading induced sympathoexcitation (Circ Res 2010). However...
Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19
Authors: Jingjing Li, Kai Zhang, Di Wu, Lianjie Ren, Xinyu Chu, Chao Qin, Xiaopeng Han, Taijun Hang, Yungen Xu, Lei Yang, Lifang Yin
Journal: Asian Journal of Pharmaceutical Sciences (2021)

Strong infectivity enables coronavirus disease 2019 (COVID-19) to rage throughout the world. Moreover, the lack of drugs with definite therapeutic effects further aggravates the spread of the pandemic. Remdesivir is one of the most promising anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) drugs. However, the limited clinical effects make its therapeutic effect controversial, which may result from the poor accumulation and activation of remdesivir in the lung. Therefore, we developed lyophilized remdesivir liposomes (Rdv-lips) which can be reconstituted as liposomal aerosol for pulmonary delivery to improve the in vivo behavior of existing remdesivir cyclodextrin conclusion compound (Rdv-cyc) injections. Liposome encapsulation endowed remdesivir with much higher solubility and better biocompatibility. The in vitro liposomal aerosol characterization demonstrated that Rdv-lips possessed a mass median aerodynamic diameter of 4.118 µm and fine particle fraction (<5 µm) higher than 50%, indicating good pulmonary delivery properties. Compared to the Rdv-cyc intravenous injection group, the Rdv-lips inhalation group displayed a nearly 100-fold increase in the remdesivir-active metabolite nucleotide triphosphate (NTP) concentration and better NTP accumulation in the lung than the Rdv-cyc inhalation group. A faster transition from remdesivir to NTP of Rdv-lips (inhalation) could also be observed due to better cell uptake. Compared to other preparations, the superiority of Rdv-lips was further evidenced by the results of an in vivo safety study, with little possibility of inducing inflammation. In conclusion, Rdv-lips for pulmonary delivery will be a potent formulation to improve the in vivo behavior of remdesivir and exert better therapeutic effects in COVID-19 treatment.
Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study
Authors: Emmanuel Gonzales, Winita Hardikar, Michael Stormon, Alastair Baker, Loreto Hierro, Dorota Gliwicz, Florence Lacaille, Alain Lachaux, Ekkehard Sturm, Kenneth D R Setchell, Ciara Kennedy, Alejandro Dorenbaum, Jana Steinmetz, Nirav K Desai, Andrew J Wardle, Will Garner, Pamela Vig, Thomas Jaecklin, Etienne M Sokal, Emmanuel Jacquemin
Journal: The Lancet (2021)
Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B.1.617.2): national case-control study
Authors: Hester Allen, Amoolya Vusirikala, Joe Flannagan, Katherine A. Twohig, Asad Zaidi, Dimple Chudasama, Theresa Lamagni, Natalie Groves, Charlie Turner, Christopher Rawlinson, Jamie Lopez-Bernal, Ross Harris, Andre Charlett, Gavin Dabrera, Meaghan Kall
Journal: The Lancet Regional Health - Europe (2021)
TCT-159 Balloon-Expandable or Self-Expandable Valves in Valve-in-Valve Transcatheter Aortic Valve Implantation?
Authors: Astrid van Nieuwkerk, Eduard Fernández-Nofrerias, Didier Tchetche, Fabio Brito, Marco Barbanti, Ran Kornowski, Azeem Latib, Augusto d’Onofrio, Flavio Ribichini, Vicente Mainar Tello, Nicolas Dumonteil, Jan Baan, Alexandre Abizaid, Samantha Sartori, Paola d’Errigo, Giuseppe Tarantini, Mattia Lunardi, Katia Orvin, Matteo Pagnesi, Angie Ghattas, George Dangas, Roxana Mehran, Ronak Delewi
Journal: Journal of the American College of Cardiology (2021)
Well‐Defined Mannosylated Polymer for Peptide Vaccine Delivery with Enhanced Antitumor Immunity
Authors: Shixian Lv, Kefan Song, Albert Yen, David J. Peeler, Dinh Chuong Nguyen, Audrey Olshefsky, Meilyn Sylvestre, Selvi Srinivasan, Patrick S. Stayton, Suzie H. Pun
Journal: Advanced Healthcare Materials (2021)

Peptide-based cancer vaccines offer production and safety advantages but have had limited clinical success due to their intrinsic instability, rapid clearance, and low cellular uptake. Nanoparticle-based delivery vehicles can improve the in vivo stability and cellular uptake of peptide antigens. Here, a well-defined, self-assembling mannosylated polymer is developed for anticancer peptide antigen delivery. The amphiphilic polymer is prepared by reversible addition-fragmentation chain transfer (RAFT) polymerization, and the peptide antigens are conjugated to the pH-sensitive hydrophobic block through the reversible disulfide linkage for selective release after cell entry. The polymer-peptide conjugates self-assemble into sub-100 nm micelles at physiological pH and dissociate at endosomal pH. The mannosylated micellar corona increases the accumulation of vaccine cargoes in the draining inguinal lymph nodes and facilitates nanoparticle uptake by professional antigen presenting cells. In vivo studies demonstrate that the mannosylated micelle formulation improves dendritic cell activation and enhances antigen-specific T cell responses, resulting in higher antitumor immunity in tumor-bearing mice compared to free peptide antigen. The mannosylated polymer is therefore a simple and promising platform for the delivery of peptide cancer vaccines.
Efficacy of non-invasive brain stimulation on global cognition and neuropsychiatric symptoms in Alzheimer’s disease and mild cognitive impairment: A meta-analysis and systematic review
Authors: Johannes Teselink, Kritleen K. Bawa, Grace KY Koo, Krushnaa Sankhe, Celina S. Liu, Mark Rapoport, Paul Oh, Susan Marzolini, Damien Gallagher, Walter Swardfager, Nathan Herrmann, Krista L. Lanctôt
Journal: Ageing Research Reviews (2021)
Global urbanicity is associated with brain and behaviour in young people
Authors: Jiayuan Xu, Xiaoxuan Liu, Qiaojun Li, Ran Goldblatt, Wen Qin, Feng Liu, Congying Chu, Qiang Luo, Alex Ing, Lining Guo, Nana Liu, Huaigui Liu, Conghong Huang, Jingliang Cheng, Meiyun Wang, Zuojun Geng, Wenzhen Zhu, Bing Zhang, Weihua Liao, Shijun Qiu, Hui Zhang, Xiaojun Xu, Yongqiang Yu, Bo Gao, Tong Han, Guangbin Cui, Feng Chen, Junfang Xian, Jiance Li, Jing Zhang, Xi-Nian Zuo, Dawei Wang, Wen Shen, Yanwei Miao, Fei Yuan, Su Lui, Xiaochu Zhang, Kai Xu, Longjiang Zhang, Zhaoxiang Ye, Tobias Banaschewski, Gareth J. Barker, Arun L. W. Bokde, Herta Flor, Antoine Grigis, Hugh Garavan, Penny Gowland, Andreas Heinz, Rüdiger Brühl, Jean-Luc Martinot, Eric Artiges, Frauke Nees, Dimitri Papadopoulos Orfanos, Herve Lemaitre, Tomáš Paus, Luise Poustka, Lauren Robinson, Sarah Hohmann, Juliane H. Fröhner, Michael N. Smolka, Henrik Walter, Robert Whelan, Jeanne Winterer, Kevin Patrick, Vince Calhoun, Mulin Jun Li, Meng Liang, Peng Gong, Edward D. Barker, Nicholas Clinton, Andre Marquand, Le Yu, Chunshui Yu, Gunter Schumann
Journal: Nature Human Behaviour (2021)
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of <i>CDX2</i> and <i>IDH1/2</i> mutations
Authors: Takahiko Yasuda, Masashi Sanada, Masahito Kawazu, Shinya Kojima, Shinobu Tsuzuki, Hiroo Ueno, Eisuke Iwamoto, Yuka Iijima-Yamashita, Tomomi Yamada, Takashi Kanamori, Rieko Nishimura, Yachiyo Kuwatsuka, Satoru Takada, Masatsugu Tanaka, Shuichi Ota, Nobuaki Dobashi, Etsuko Yamazaki, Asao Hirose, Tohru Murayama, Masahiko Sumi, Shinya Sato, Naoyuki Tange, Yukinori Nakamura, Yuna Katsuoka, Emiko Sakaida, Toyotaka Kawamata, Hiroatsu Iida, Yuichi Shiraishi, Yasuhito Nannya, Seishi Ogawa, Masafumi Taniwaki, Norio Asou, Yoshihiro Hatta, Hitoshi Kiyoi, Itaru Matsumura, Keizo Horibe, Hiroyuki Mano, Tomoki Naoe, Yasushi Miyazaki, Fumihiko Hayakawa
Journal: Blood (2021)